Search results for "Muscle Neoplasms"

showing 4 items of 4 documents

Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.

2001

The expression of cysteine proteinases cathepsins B and K and of the endogenous inhibitor of cysteine proteinases, cystatin C, was investigated in tissue specimens of patients with giant cell tumor of tendon sheath (GCTTS). Expression of both enzymes was examined by immunohistochemistry in tissue specimens of 14 patients with GCTTS. Applying double-labeling techniques, the coexpression of cathepsin B and its major endogenous inhibitor cystatin C was additionally studied. Cells expressing the respective proteins were further characterized with the macrophage markers HAM56 and anti-CD68 (clone PG-M1). Cathepsin B could be detected in numerous HAM56-positive mononuclear cells (MC), but only in…

AdultMaleCathepsin KAntigens Differentiation MyelomonocyticCathepsin ECell CountCathepsin FBiologyCysteine Proteinase InhibitorsGiant CellsCathepsin BPathology and Forensic MedicineCathepsin CCathepsin BImmunoenzyme TechniquesTendonsCathepsin OCathepsin HAntigens CDCathepsin L1HumansCystatin CCathepsin SAgedMuscle NeoplasmsGiant Cell TumorsAntibodies MonoclonalMiddle AgedMolecular biologyCathepsinsCystatinsBiochemistryLeukocytes MononuclearFemaleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer

2020

Abstract Background The cell surface interleukin 22 (IL-22) receptor complex is mainly expressed in epithelial and tissue cells like pancreatitis cells. Recent studies described that IL-22R was overexpressed in malignant diseases and was associated with a poor overall survival (OS). The role of IL-22RA1 gene expression in muscle invasive bladder cancer (MIBC) has not been investigated, yet. Objectives The aim of this study was to analyze the role of IL-22RA1 gene expression in patients with MIBC. Methods In a cohort of 114 patients with MIBC who underwent radical cystectomy, IL-22RA1 gene expression was analyzed with qRT-PCR and correlated with clinical parameters. Furthermore, Kaplan-Meier…

AdultMaleOncologymedicine.medical_specialtyReceptor complexUrologymedicine.medical_treatment030232 urology & nephrologyCystectomyCohort StudiesCystectomyInterleukin 2203 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineHumansNeoplasm InvasivenessAgedAged 80 and overMuscle NeoplasmsBladder cancerProportional hazards modelbusiness.industryReceptors InterleukinMiddle AgedPrognosismedicine.diseaseSurvival RateUrinary Bladder NeoplasmsOncology030220 oncology & carcinogenesisCohortT-stageFemalebusinessFollow-Up StudiesUrologic Oncology: Seminars and Original Investigations
researchProduct

Posterior compartment of the lower leg reconstruction with free functional rectus femoris transfer after sarcoma resection.

2009

A 72-year-old man with the third recurrence of a low-grade liposarcoma of the right lower leg came to our attention seeking limb-salvage surgery. The tumour was removed en bloc with all the superficial posterior compartment of the leg. Appropriate foot flexion was restored by means of a free-functional rectus femoris musculocutaneous flap harvested from the ipsilateral thigh. The patient was kept on a postoperative splint for 6 weeks. Three months after the operation, clinical and elecromyographic signs of reinnervation were observed. The patient was able to walk, run and climb stairs and no donor-site morbidity was observed. Thigh extension was rated M4, comparable to the contralateral thi…

Malemedicine.medical_specialtymedicine.medical_treatmentPosterior compartment of the lower leg reconstruction with free functional rectus femoris transfer after sarcoma resection.LiposarcomaThighSurgical FlapsQuadriceps MuscleMedicineHumansSurgical FlapsCompartment (pharmacokinetics)Anterior compartment of thighAgedLegMuscle Neoplasmsbusiness.industryAnatomyLiposarcomaPlastic Surgery Proceduresmedicine.diseaseLimb SalvageSurgerybody regionsmedicine.anatomical_structureSurgerySarcomaNeoplasm Recurrence LocalbusinessSplint (medicine)ReinnervationJournal of plastic, reconstructiveaesthetic surgery : JPRAS
researchProduct

Time-point and dosage of gene inactivation determine the tumor spectrum in conditional Ptch knockouts

2009

Mutations in Patched (PTCH) have been associated with tumors characteristic both for children [medulloblastoma (MB) and rhabdomyosarcoma (RMS)] and for elderly [basal cell carcinoma (BCC)]. The determinants of the variability in tumor onset and histology are unknown. We investigated the effects of the time-point and dosage of Ptch inactivation on tumor spectrum using conditional Ptch-knockout mice. Ptch heterozygosity induced prenatally resulted in the formation of RMS, which was accompanied by the silencing of the remaining wild-type Ptch allele. In contrast, RMS was observed neither after mono- nor biallelic postnatal deletion of Ptch. Postnatal biallelic deletion of Ptch led to BCC preca…

PatchedPatched ReceptorsCancer ResearchPathologymedicine.medical_specialtyAgingSkin NeoplasmsGene DosageReceptors Cell SurfaceBiologymedicine.disease_causeGene dosageGastrointestinal epitheliumLoss of heterozygosity03 medical and health sciencesMice0302 clinical medicineRhabdomyosarcomamedicineAnimalsGene SilencingRhabdomyosarcomaMuscle SkeletalGerm-Line MutationPeritoneal Neoplasms030304 developmental biologyGastrointestinal NeoplasmsMedulloblastomaMice Knockout0303 health sciencesMutationMuscle NeoplasmsCystsGeneral MedicinePTCH1 Genemedicine.disease3. Good healthPatched-1 Receptorstomatognathic diseasesCarcinoma Basal Cell030220 oncology & carcinogenesisMutationCancer researchPrecancerous ConditionsCarcinogenesis
researchProduct